Barclays PLC Acquires 48,639 Shares of MacroGenics, Inc. (NASDAQ:MGNX)

Barclays PLC increased its holdings in shares of MacroGenics, Inc. (NASDAQ:MGNX) by 97.1% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 98,753 shares of the biopharmaceutical company’s stock after purchasing an additional 48,639 shares during the quarter. Barclays PLC owned approximately 0.16% of MacroGenics worth $325,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in the business. China Universal Asset Management Co. Ltd. grew its holdings in shares of MacroGenics by 64.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 12,064 shares of the biopharmaceutical company’s stock valued at $40,000 after acquiring an additional 4,707 shares in the last quarter. Stifel Financial Corp boosted its position in MacroGenics by 19.7% during the third quarter. Stifel Financial Corp now owns 39,888 shares of the biopharmaceutical company’s stock valued at $131,000 after purchasing an additional 6,578 shares during the last quarter. XML Financial LLC grew its stake in MacroGenics by 66.0% in the third quarter. XML Financial LLC now owns 17,600 shares of the biopharmaceutical company’s stock valued at $58,000 after purchasing an additional 7,000 shares in the last quarter. XTX Topco Ltd acquired a new position in shares of MacroGenics during the 3rd quarter worth approximately $37,000. Finally, DRW Securities LLC bought a new stake in shares of MacroGenics during the 2nd quarter worth approximately $56,000. Institutional investors own 96.89% of the company’s stock.

MacroGenics Trading Down 1.0 %

NASDAQ:MGNX opened at $3.00 on Monday. The stock has a 50 day simple moving average of $3.39 and a 200 day simple moving average of $3.69. The stock has a market cap of $188.29 million, a P/E ratio of -1.90 and a beta of 2.04. MacroGenics, Inc. has a 1-year low of $2.95 and a 1-year high of $21.88.

Analyst Ratings Changes

MGNX has been the topic of a number of recent analyst reports. JMP Securities downgraded shares of MacroGenics from an “outperform” rating to a “market perform” rating in a report on Thursday, November 7th. HC Wainwright restated a “neutral” rating and set a $4.00 price objective on shares of MacroGenics in a research note on Wednesday, November 6th. Finally, StockNews.com upgraded shares of MacroGenics from a “sell” rating to a “buy” rating in a research note on Sunday, November 10th. Eight equities research analysts have rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, MacroGenics has an average rating of “Hold” and a consensus target price of $7.63.

MacroGenics Profile

MacroGenics, Inc, a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.